# FDA 483 - Kyle Coleman, M.D. - March 20, 2019

Source: https://www.globalkeysolutions.net/records/483/kyle-coleman-md/1cca5eb9-369e-4fbb-8c01-e1af645ea298

> FDA 483 for Kyle Coleman, M.D. on March 20, 2019. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Kyle Coleman, M.D.
- Inspection Date: 2019-03-20
- Product Type: drugs
- Office Name: New Orleans District Office
- Summary: An FDA inspection of Kyle M. Coleman, MD, PI, a clinical investigator in New Orleans, LA, conducted from March 18-20, 2019, identified a significant deficiency in investigational drug disposition records. The firm failed to maintain adequate records regarding the dates and quantities of investigational drug product returned by subjects. This indicates a lack of proper accountability for investigational products during the clinical trial.

## Related Officers

- [issuing_officer](https://www.globalkeysolutions.net/people/laura-l-staples/fe59bc9c-b439-4dd8-8c8a-5fac6f7733f8)

Company: https://www.globalkeysolutions.net/companies/kyle-coleman-md/b756ec84-f915-4849-a733-6953a7bdc43a

Office: https://www.globalkeysolutions.net/offices/new-orleans-district-office/95352142-b992-4e06-849d-d7483c0959ea